Medical device company Artivion (NYSE:AORT) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 18.4% year on year to $113.4 million. The company’s full-year revenue guidance of $442 million at the midpoint came in 0.9% above analysts’ estimates. Its non-GAAP profit of $0.16 per share was in line with analysts’ consensus estimates. Is now the time to buy Artivion? Find out in our full research report. Artivion (AORT) Q3 CY2025 Highlights: Revenue: $113.4 million vs analyst estimates of $ ...